
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is a promising biopharmaceutical company that has shown success in clinical trials with their CAR-T therapy, Aucatzyl, for the treatment of various cancers and autoimmune diseases. The company also has a diversified pipeline and is expanding into the treatment of progressive multiple sclerosis, providing potential for significant revenue growth. While there are risks associated with clinical trials and regulatory requirements, Autolus' projected sales and revenue growth show promise for their long-term success in the market.
Bears say
Autolus Therapeutics is experiencing slow growth in their lead product candidate, Aucatzyl, and faces challenges in establishing reimbursement policies in key markets. Furthermore, their pipeline is relatively early-stage, and their programs face risks including potential adverse events and eventual disease progression. Given their limited revenue and reliance on patents for protection, there are significant financial risks associated with investing in AUTL.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares